Sotio Stops IL-15 Trials As Cytokine Falls Short in Solid Tumors, Dealing Fresh Blow to Once-Hot Mechanism

A look at interim data on nanrilkefusp alfa, also known as SOT101, has revealed “insufficient efficacy to warrant further development in larger randomized trials” in the settings targeted to date, prompting Sotio to immediately stop enrollment in three studies.